EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

First‐Line PD ‐1 Inhibitor‐Based Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Revised Systematic Review and Meta‐Analysis of Phase III Trials

Vincent Rothweiler, Christoph Roderburg, Muemtaz Koeksal iD, Björn Erik Ole Jensen iD, Torsten Feldt iD, Ilyas Gencer, Johannes C Fischer iD, Wilfried Budach, Wolfram Trudo Knoefel, Guangyu Lu iD, Edwin Bölke iD

Cancer Reports · 2026

DOI: 10.1002/cnr2.70660 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer Reports, 2026. Verfasst von Vincent Rothweiler und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical School of Heinrich Heine University Düsseldorf, Düsseldorf, Germany. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Immune Checkpoint Inhibitors, Esophageal Squamous Cell Carcinoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Immune checkpoint blockade has changed the first‐line treatment landscape for advanced esophageal squamous cell carcinoma (ESCC), but the magnitude and consistency of benefit across phase III trials require careful synthesis.

Methods

We conducted a PRISMA 2020‐guided systematic review of PubMed, Embase, CENTRAL, and Web of Science (January 1, 2015 to April 30, 2025) for phase III randomized trials comparing first‐line PD‐1 inhibitor‐based therapy with chemotherapy in advanced/metastatic ESCC. The primary endpoint was overall survival (OS). Secondary endpoints were safety and prespecified subgroup outcomes. RoB 2 was used for risk‐of‐bias assessment; certainty of evidence was judged with GRADE. A fixed‐effect inverse‐variance model was prespecified for the primary common‐effect analysis, with random‐effects and sensitivity analyses performed secondarily.

Results

Six eligible phase III trials were included in the primary analysis (KEYNOTE‐590 ESCC subgroup, CheckMate‐648 nivolumab‐plus‐chemotherapy arm, ESCORT‐1st, JUPITER‐06, ORIENT‐15, and RATIONALE‐306). Across the six parent‐trial reports, 4137 patients were randomized overall; for pooling, KEYNOTE‐590 was restricted to the prespecified ESCC subgroup and CheckMate‐648 to the nivolumab‐plus‐chemotherapy comparison. PD‐1 inhibitor‐based therapy significantly improved OS versus chemotherapy alone (pooled HR 0.68, 95% CI: 0.63–0.74; I 2 = 0%, interpreted as low statistical heterogeneity with caution because only six studies were pooled). Qualitative assessment indicated that the treatment effect was generally larger in PD‐L1‐high populations; however, biomarker‐defined subgroup data were not sufficiently harmonized for formal pooling, and the magnitude of benefit in very low or PD‐L1‐negative disease remains uncertain. Grade ≥ 3 treatment‐related adverse events were common in both arms, whereas immune‐related toxicities were more frequent with PD‐1 inhibitor‐based therapy and required active monitoring.

Conclusion

First‐line PD‐1 inhibitor‐based therapy confers a robust OS benefit in advanced/metastatic ESCC and supports chemoimmunotherapy as a contemporary standard of care. Remaining uncertainties relate mainly to biomarker‐negative disease, assay heterogeneity, and cross‐trial differences in chemotherapy backbone and geographic composition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsImmune Checkpoint InhibitorsEsophageal Squamous Cell CarcinomaAntineoplastic Combined Chemotherapy ProtocolsHumansProgrammed Cell Death 1 ReceptorClinical Trials, Phase III as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

ESCCPD‐1 inhibitorPD‐L1esophageal squamous cell carcinomaimmunotherapymeta‐analysisoverall survival

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPDCD1 protein, human

Autor:innen und Institutionen

  • Medical School of Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Department of Radiation Oncology, University Hospital OWL, Klinikum Bielefeld, Bielefeld, Germany.
  • Institute for Transplantation Diagnostics and Cellular Therapeutics, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Department of Surgery, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • School of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Yangzhou University, Yangzhou, China.

ORCID-Profile: Muemtaz Koeksal, Björn Erik Ole Jensen, Torsten Feldt, Johannes C Fischer, Guangyu Lu, Edwin Bölke

Zitieren

APA

Rothweiler, V., Roderburg, C., Koeksal, M., Jensen, B. E. O., Feldt, T., Gencer, I., Fischer, J. C., Budach, W., Knoefel, W. T., Lu, G., & Bölke, E. (2026). First‐Line PD ‐1 Inhibitor‐Based Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Revised Systematic Review and Meta‐Analysis of Phase III Trials. Cancer Reports. https://doi.org/10.1002/cnr2.70660

Vancouver

Rothweiler V, Roderburg C, Koeksal M, Jensen BEO, Feldt T, Gencer I, et al. First‐Line PD ‐1 Inhibitor‐Based Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Revised Systematic Review and Meta‐Analysis of Phase III Trials. Cancer Reports. 2026. doi:10.1002/cnr2.70660

BibTeX
@article{Rothweiler2026,
  author = {Rothweiler, Vincent and Roderburg, Christoph and Koeksal, Muemtaz and Jensen, Björn Erik Ole and Feldt, Torsten and Gencer, Ilyas and Fischer, Johannes C and Budach, Wilfried and Knoefel, Wolfram Trudo and Lu, Guangyu and Bölke, Edwin},
  title = {First‐Line PD ‐1 Inhibitor‐Based Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Revised Systematic Review and Meta‐Analysis of Phase III Trials},
  journal = {Cancer Reports},
  year = {2026},
  doi = {10.1002/cnr2.70660}
}
Kostenlos starten →